# A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV

> **NCT03755167** · PHASE2 · SUSPENDED · sponsor: **Immunity Pharma Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** IPL344

## Key facts

- **NCT ID:** NCT03755167
- **Lead sponsor:** Immunity Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-12-09
- **Primary completion:** 2027-01
- **Final completion:** 2027-02
- **Target enrollment:** 15 (ESTIMATED)
- **Why stopped:** Study was suspended due to IPL344 shortage and may resume once drug supply is available. Survival follow-up is still ongoing following participants' consent
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755167, "A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03755167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*